Psychedelic Mushrooms Market Size And Trends

The global psychedelic mushrooms market size is likely to be valued at US$ 1.83 billion in 2025, reaching US$ 3.63 billion by 2032 and exhibiting a CAGR of 10.3% during the forecast period 2025-2032. Increasing therapeutic acceptance of psychedelics and expanding legalization of the use of certain substances for recreational purposes in several countries are the foremost growth drivers. 

Recent Market Trends 

• Supported by strong research, psychedelic mushrooms are gaining popularity for treating depression, anxiety, PTSD, and addiction, reflecting a major trend in mental wellness and holistic treatment approaches. 
• Technological advancements such as controlled-environment agriculture and nanotechnology have enhanced the cultivation quality and psilocybin extraction, aiding more efficient clinical applications and higher product purity. 
• De-addiction applications currently dominate the market, propelled by the rapid adoption of psychedelic-assisted therapies for addiction treatment and promising clinical trial outcomes. 
• Key industry players such as MindMed, Atai Life Sciences, and Compass Pathways control approximately 45% of the market through pioneering clinical trials and proprietary therapeutic platforms. 

Psychedelic Mushrooms Market in the News 

• July 2025: A newly published study by Emory University researchers found that psilocin, the active metabolite of psilocybin, extended the lifespan of human skin and lung cells by over 50% and significantly improved survival rates in aged mice, with treated mice exhibiting better fur quality, reduced graying, and visible hair regrowth. The findings suggest that psilocybin may act on multiple aging mechanisms such as reducing oxidative stress, enhancing DNA repair responses, and preserving telomere length. 
• June 2025: Compass Pathways announced that its Phase III trial of COMP360, a synthetic psilocybin treatment, achieved its primary endpoint, demonstrating a statistically significant 3.6-point reduction in depressive symptoms compared to placebo. Despite these results being deemed clinically meaningful, investor sentiment was tepid, as evidenced by a roughly 36% drop in the company's stock price. The company plans to discuss these preliminary findings with the FDA and awaits 26-week data from its companion COMP006 trial to provide a more complete picture.  
• May 2025: Connecticut’s House of Representatives approved House Bill 7065 to decriminalize possession of up to half an ounce of psilocybin mushrooms, downgrading it from a Class A misdemeanor to a civil infraction punishable by a US$ 150 fine for first offenses and up to US$ 500 for subsequent violations, with the law poised to take effect on October 1, 2025, if passed by the Senate. This legislation marks another progressive step in the Northeast’s ongoing move toward psychedelic reform, joining states like Oregon, Colorado, and New Mexico in reassessing drug policy. 

Segment Analysis 

The dominance of the Psilocybe species, which constitutes the largest product category, is due to its well-documented therapeutic benefits and regulatory approvals for clinical use. Gymnopilus and Panaeolus mushrooms represent emerging categories but currently hold a smaller market share as research in these species is still nascent. Product forms have been divided into fresh or whole, dried, and processed mushrooms, with a clear consumer preference for fresh or whole mushrooms, showing a clear demand for natural, minimally processed therapeutic options. In terms of application, addiction management is gathering rapid momentum as the fastest-growing niche. The rising global prevalence of mental health disorders, coupled with growing consumer awareness about the efficacy of psychedelic mushrooms, is driving demand across diverse applications. This expanding awareness, paired with the science-backed therapeutic promise of psilocybin compounds, is propelling market penetration and acceptance across a wide spectrum of demographics. 

Regional Analysis 

Regionally, North America is expected to lead the psychedelic mushrooms market share in 2025 as a result of a confluence of factors in the form of progressive regulatory frameworks for recreational drugs, substantial investments in clinical research, and widespread acceptance of psychedelic therapeutics by healthcare providers. The United States, in particular, is a hotbed for clinical trials and venture capital investment focused on psilocybin-based treatments. Europe is also a significant market, fueled by regulatory adaptations in countries such as the U.K., the Netherlands, and Germany, which facilitate broader access to psychedelic-assisted therapies and ongoing research initiatives.  

Asia Pacific is gaining ground due to the growing interest in traditional and modern therapeutic uses of mushrooms, with Thailand pioneering decriminalization and research programs. Despite Latin America and the Middle East & Africa being at the nascent stages of development, the rise in global momentum around psychedelic therapy, coupled with evolving regulations is expected to stimulate growth in these regions.  

Industry Players 

Industry competitors in the global psychedelic mushrooms landscape are marked by the predominance of innovative biotech companies and pharmaceutical pioneers such as MindMed, Atai Life Sciences, and Compass Pathways, which collectively hold nearly 45% of the market share. These companies are focused on developing proprietary therapeutic platforms and are advancing multiple clinical trials to validate psychedelic mushroom-based medicines for mental health treatments.  

Their strengths lie in scalable production processes, improved drug delivery technologies, and navigating complex regulatory landscapes to secure approvals and commercialize products globally. Emerging biotech startups and wellness enterprises are also entering the market, leveraging the rising consumer interest in natural de-addiction therapies and mental wellness products.